Last 3,448
Change Today 0.00 / 0.00%
Volume 0.0
CGEN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Tel Aviv
As of 10:24 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Open
$3,465
Previous Close
$3,372
Day High
$3,477
Day Low
$3,417
52 Week High
02/27/14 - $4,700
52 Week Low
11/17/14 - $2,454
Market Cap
1.7B
Average Volume 10 Days
31.8K
EPS TTM
$-0.82
Shares Outstanding
48.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMPUGEN LTD (CGEN)

compugen ltd (CGEN) Related Businessweek News

No Related Businessweek News Found

compugen ltd (CGEN) Details

Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

Founded in 1993

compugen ltd (CGEN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

compugen ltd (CGEN) Key Developments

Felix Karim Joins Compugen as Vice President Corporate & Business Development, Effective March 2, 2015

Compugen Ltd. announced the appointment of Dr. Felix Karim as Vice President Corporate & Business Development, effective March 2, 2015. Dr. Karim, who will be based at Compugen's South San Francisco facilities, will report to Dr. Anat Cohen-Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for the company's business development strategy and its execution. Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. His most recent position prior to joining Compugen was Head of External R&D (licensing) for the San Francisco region at Amgen.

Compugen Ltd. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Compugen Ltd. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss for of $1.5 million, or $0.03 per basic and diluted share, compared with a net loss of $2.9 million, or $0.09 per diluted share, in the comparable period of 2013. The company posted revenues for the fourth quarter of 2014 of $6.6 million compared with $1.8 million in the comparable period of 2013. The increase in revenues is attributable to the milestone payments in the amount of $7.2 million and the relevant portion of the non-refundable upfront payment, both relating to the August 2013 collaboration and license agreement with Bayer HealthCare. Operating loss was $1.12 million against $3.96 million a year ago. Net loss before taxes was $1.18 million against $2.58 million a year ago. For the year, the company reported revenues of $12.37 million against $3.5 million a year ago. Operating loss was $12.34 million against $17.04 million a year ago. Net loss before taxes was $10.73 million against $13.58 million a year ago. Net loss was $11.09 million or $0.23 basic and diluted per share against $14.08 million or $0.36 basic and diluted per share a year ago.

Compugen Ltd. to Report Q4, 2014 Results on Feb 10, 2015

Compugen Ltd. announced that they will report Q4, 2014 results at 10:00 AM, US Eastern Standard Time on Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:IT 3,448.00 0.00

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
View Industry Companies
 

Industry Analysis

CGEN

Industry Average

Valuation CGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMPUGEN LTD, please visit www.cgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.